Insider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires 13,037 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe bought 13,037 shares of the stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $17.13 per share, for a total transaction of $223,323.81. Following the acquisition, the chief executive officer now owns 705,548 shares of the company’s stock, valued at $12,086,037.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mark Lappe also recently made the following trade(s):

• On Thursday, September 12th, Mark Lappe acquired 26,963 shares of Inhibrx stock. The stock was purchased at an average price of $15.05 per share, with a total value of $405,793.15.
• On Monday, September 9th, Mark Lappe bought 9,500 shares of Inhibrx stock. The shares were acquired at an average price of $15.21 per share, for a total transaction of $144,495.00.
• On Friday, September 6th, Mark Lappe purchased 26,000 shares of Inhibrx stock. The stock was acquired at an average cost of $15.29 per share, with a total value of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe acquired 20,000 shares of Inhibrx stock. The shares were acquired at an average cost of $15.81 per share, for a total transaction of $316,200.00.
• On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were bought at an average price of $14.03 per share, for a total transaction of $140,300.00.

Inhibrx Stock Down 1.3 %

Shares of INBX stock opened at $16.99 on Thursday. The stock has a fifty day moving average price of $13.87 and a 200 day moving average price of $23.42. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter. As a group, equities analysts forecast that Inhibrx, Inc. will post 87.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities assumed coverage on shares of Inhibrx in a research note on Tuesday, July 23rd. They issued a “market perform” rating for the company.

Hedge Funds Weigh In On Inhibrx

Institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC acquired a new stake in shares of Inhibrx during the fourth quarter valued at $26,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Inhibrx by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 30,561 shares of the company’s stock worth $1,068,000 after purchasing an additional 744 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Inhibrx by 8.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after purchasing an additional 1,112 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Inhibrx by 7.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,920 shares of the company’s stock worth $766,000 after buying an additional 1,426 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Inhibrx by 8.5% in the first quarter. Swiss National Bank now owns 42,000 shares of the company’s stock valued at $1,468,000 after buying an additional 3,300 shares during the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.